Evidence map›Paper›PMID 42635933›Full record

ArticleMolecular biomedicine2026

miR-486-5p suppresses autophagy in hepatocellular carcinoma via activation of the AKT/mTOR signalling pathway.

Yazheng Li, Mei Hou, Yong Jin, Xiangjin Zhuang, Yueyi Li, Wen Yang, Hongyang Wang, Qiyu Feng

Abstract read
In one paragraph

Article in Molecular biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yazheng Li *Cancer Research Center, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China.
Mei Hou *Cancer Research Center, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China.
Yong JinCancer Research Center, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China.
Xiangjin ZhuangCancer Research Center, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China.
Yueyi LiCenter for MPACC & MEM, Huazhong University of Science and Technology, Wuhan, 430074, China.
Wen YangCancer Research Center, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China. woodeasy66@hotmail.com.
Hongyang WangCancer Research Center, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China. hywangk@vip.sina.com.
Qiyu FengCancer Research Center, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China. qiyu@icloud.com.ORCID http://orcid.org/0000-0003-2715-0087

Funding

National Natural Science Foundation of China 81773112National Natural Science Foundation of China 82073186
6 · The paper itself

Abstract

Autophagy is controlled by a complex signalling network and is closely linked to the initiation and progression of hepatocellular carcinoma (HCC). However, how microRNAs (miRNAs) regulate autophagy in HCC remains incompletely understood. In this study, we identified microRNA-486-5p (miR-486-5p) as a tumour-associated microRNA that is enriched in circulating exosomes derived from patients with HCC. Elevated miR-486-5p promoted proliferation and suppressed apoptosis in HCC cell lines under stress conditions. Mechanistically, miR-486-5p directly targets the 3' untranslated region of the phosphatase and tensin homologue (PTEN) gene, thereby decreasing the production of the PTEN protein and consequently leading to the activation of the protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signalling pathway. This phenomenon was accompanied by the inhibitory phosphorylation of unc-51 like autophagy-activating kinase 1 (ULK1), which resulted in impaired autophagy. The pharmacological inhibition of AKT or mTOR led to the restoration of autophagy and the attenuation of miR-486-5p-driven growth and survival advantages. Furthermore, the transcription factor MYB was found to bind the promoter of ankyrin-1 (ANK1), the host gene of miR-486-5p, and to drive its expression. In an orthotopic liver tumour model, the liver-targeted delivery of miR-486-5p accelerated tumour expansion, an effect that was reversed by AKT or mTOR blockade. Collectively, these findings delineate a MYB/miR-486-5p/PTEN/AKT/mTOR signalling axis that constrains autophagy to facilitate HCC progression, suggesting potential avenues for biomarker development and therapeutic intervention.

Indexed as

AutophagyCarcinoma, HepatocellularLiver NeoplasmsMicroRNAsProto-Oncogene Proteins c-aktSignal TransductionTOR Serine-Threonine KinasesAnimalsApoptosisCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansMaleProto-Oncogene Proteins c-mybPTEN PhosphohydrolaseMicroRNAsMIRN486 microRNA, humanMTOR protein, humanProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-mybPTEN PhosphohydrolasePTEN protein, humanTOR Serine-Threonine KinasesAutophagyHepatocellular carcinomaMiR-486-5pMYBPTEN

Identifiers

PMID42635933
PMCPMC13504038

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.